Built by Stanford Researchers
You have been
let down by
the system.
So have the researchers trying to help you. The Lancet has recognized it: long COVID research is drowning in underfunding. Your free email signup can change that.
The field lacks the diagnostic tools needed to stratify patients for clinical trials. Without stratification, treatment trials struggle. Without trials, patients wait.
We are building those tools, as a research program first, with clinical validation through partner clinics, and a long-term goal of a regulated diagnostic.
The only way this gets made is if we spin out and raise capital, and the only way we raise capital is if investors see real demand. That's where your free signup comes in.
Our immediate goal is to get accepted into Y Combinator, a startup accelerator. The application deadline is May 4. Between now and then, every signup is a positive signal, and every share is a multiplier.
Y Combinator deadline
Investor mood
Skeptical
“Is long COVID even real?”
Skeptical
0
Intrigued
500
Ecstatic
5,000+
Be the first to know.
We'll let you know when research participation opens at a clinic near you, and when our work progresses toward clinical availability.
Free to join. No payment, no commitment.
Nothing to pay, nothing to buy. Your email stays private.
We are a Stanford-affiliated research program studying the biology of long COVID. In collaboration with clinics treating long COVID patients, we are running a proteome-wide autoantibody study to understand what distinguishes patient subgroups, and to build the diagnostic tools the field is missing.
Our spin-out company Muno Biotech currently has two promising diagnostic tools under development:
1. A long COVID subtyping blood test.
Uses a panel of 250+ autoantigens to stratify patients into biological subtypes. Different subtypes likely need different treatments, and until now, doctors have had no way to tell them apart.
2. A viral persistence blood test.
Analyzes your B-cells (your immune system's antibody-producing cells) with a machine learning algorithm we developed. It detects whether your immune system is still actively producing antibodies against SARS-CoV-2 Spike: a direct signal of viral persistence.
Both viral persistence and autoimmunity are now among the leading hypotheses for what drives long COVID. But here's what the research community keeps pointing out: without a diagnostic, pharma won't start clinical trials. Without clinical trials, no treatments get developed. This is the bottleneck the VIPER whitepaper laid out in detail.
Here's what we're actually asking:
To keep developing these tests, we need venture capital. We're applying to Y Combinator. If we can show investors real interest from the long COVID community, our chances of raising capital increase.
Every email you add is a data point investors can't ignore. Every share in a long COVID community, every post on Reddit, every message to your support group matters now, more than it will in a month.
Sign up. Share this. Help us, help you.
Signed,
Jo Teichmann & Linda Lan, PhD
Co-founders, Muno Biotech · Stanford researchers
What the test actually does
250+ autoantigens,
5 clinical subtypes.
Long COVID is not one disease. Different patients have different biological drivers, and that is likely why one-size-fits-all trials have struggled. Our intended panel measures autoantibodies against 250+ curated human proteins and aims to map the signal onto five symptom-based subtypes: neurocognitive, cardiorespiratory, GI, musculoskeletal, and sensory.
Autoantibody panel · spinning structures are autoantibody-target complexes
How we picked the 250+
Every target is backed by peer-reviewed evidence. We screened the published long COVID autoantibody literature across OpenAlex, PubMed, and Semantic Scholar, pulled out the studies that actually measure autoantigens in patient cohorts, and combined those candidates with our own preliminary findings onto one panel.
Preliminary findings
We see the subtyping signal
in our first 78 samples.
We ran the HuProt™ human proteome array, which measures over 17,000 full-length human proteins, on blood from 53 long COVID patients, 11 non-long COVID controls (people who had COVID and recovered), and 14 pre-pandemic healthy donors.
Both long COVID patients and recovered controls carried roughly 2 to 3× as many positive autoantibody targets as pre-pandemic donors (p<0.001). This is consistent with post-infection immune remodeling in anyone who had COVID, regardless of whether symptoms resolved.
Within the long COVID group, we see proteins elevated over recovered controls that map onto biologically coherent axes, including targets linked to neurovascular, interferon, and neuronal pathways, aligned with mechanisms already reported in the long COVID literature. We are holding specific protein-level findings for peer review and IP registration.
The cohort is still small, which is exactly why we are raising capital to validate the results. Muno Biotech is a research-stage company. This page describes a research program, not a diagnostic product. No claims are made about diagnostic performance, clinical utility, or medical value. Nothing on this page constitutes medical advice.
Still with us?
Add your name.
Move the mood.
Investor mood
Skeptical
“Is long COVID even real?”
Skeptical
0
Intrigued
500
Ecstatic
5,000+
Be the first to know.
We'll let you know when research participation opens at a clinic near you, and when our work progresses toward clinical availability.
Free to join. No payment, no commitment.
Nothing to pay, nothing to buy. Your email stays private.